CDTX vs. CRIS, SCYX, AGTC, NTGN, XFOR, GNFT, CRBU, IPSC, ABOS, and OTLK
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Curis (CRIS), SCYNEXIS (SCYX), Applied Genetic Technologies (AGTC), Neon Therapeutics (NTGN), X4 Pharmaceuticals (XFOR), Genfit (GNFT), Caribou Biosciences (CRBU), Century Therapeutics (IPSC), Acumen Pharmaceuticals (ABOS), and Outlook Therapeutics (OTLK). These companies are all part of the "medical" sector.
Cidara Therapeutics (NASDAQ:CDTX) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability.
Curis received 248 more outperform votes than Cidara Therapeutics when rated by MarketBeat users. However, 70.29% of users gave Cidara Therapeutics an outperform vote while only 67.65% of users gave Curis an outperform vote.
Cidara Therapeutics has higher revenue and earnings than Curis. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.
Cidara Therapeutics has a net margin of -73.46% compared to Curis' net margin of -486.45%. Cidara Therapeutics' return on equity of -201.62% beat Curis' return on equity.
In the previous week, Curis had 3 more articles in the media than Cidara Therapeutics. MarketBeat recorded 4 mentions for Curis and 1 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 1.89 beat Curis' score of 0.26 indicating that Cidara Therapeutics is being referred to more favorably in the media.
Cidara Therapeutics presently has a consensus target price of $71.25, suggesting a potential upside of 438.14%. Curis has a consensus target price of $37.33, suggesting a potential upside of 510.02%. Given Curis' higher possible upside, analysts plainly believe Curis is more favorable than Cidara Therapeutics.
Cidara Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.35, suggesting that its share price is 235% more volatile than the S&P 500.
35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 7.6% of Cidara Therapeutics shares are owned by insiders. Comparatively, 5.7% of Curis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Cidara Therapeutics beats Curis on 12 of the 18 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
